Medicare AdvantageCoverageMedium impact
MA08.053b, Personalized Vaccines (e.g., Provenge®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.053b covering personalized vaccines like Provenge® has been reissued with updates effective May 28, 2025. This policy change affects coverage and billing requirements for personalized immunotherapy treatments.
Action Required
By May 28, 2025: Billing team must review updated MA08.053b policy for personalized vaccines (Provenge®) to understand new coverage criteria and documentation requirements. Update prior authorization processes and billing procedures for Medicare Advantage patients receiving personalized immunotherapy treatments.